Table 1.
Participant characteristics.
| Placebo (n = 8) | Dapivirine (n = 27) | |||||
| Baseline (n = 8) | Follow-up visitsa (n = 16) | P value | Baseline (n = 27) | Follow-up visitsa (n = 54) | P value | |
| Primary partner (n; % yes) | 4 (50%) | 8 (50%) | >0.9999 | 18 (66.7%) | 28 (52.8%) | 0.2403 |
| Vaginal sex last 30 days (all) (n; % yes) | 3 (37.5%) | 8 (50%) | 0.6792 | 15 (55.6%) | 25 (47.2%) | 0.4852 |
| Vaginal sex with condom last 30 days (n; % yes) | 3 (37.5%) | 7 (43.8%) | >0.9999 | 14 (51.8%) | 24 (45.3%) | 0.6381 |
| Vaginal sex without condom last 30 days (n; % yes) | 2 (25%) | 5 (31.3%) | >0.9999 | 8 (29.6%) | 14 (26.4%) | 0.7933 |
| Oral sex last 30 days (receptive) (n; % yes) | 3 (37.5%) | 3 (18.8%) | 0.3618 | 10 (37.0%) | 21 (38.9%) | >0.999 |
| Anal sex last 30 days (n; % yes) | 0 (0%) | 0 (0%) | N/A | 1 (3.7%) | 1 (1.9%) | N/A |
| Ring use last 30 days (n; % yes) | N/A | 16 (100%) | N/A | 53 (98.1%) | >0.9999b | |
a
Follow-up visits were pooled for each treatment arm.
b
Fisher's exact test comparing ring use between placebo and dapivirine arms. All other P values represent Fisher's exact tests comparing baseline versus all follow-up visits in each arm.